PDCD1 and neoplasm: Both in vitro and in vivo experiments demonstrated that the combination of MK1775 and anti–PD-1 antibody markedly suppressed tumor growth by enhancing the immune sensitivity of the tumor microenvironment through coordinated metabolic and immunological regulation (Chen et al., 2024; Ping et al., 2025).